

1 **Title Page**

2

3 **The association of ethnicity and oncologic outcomes for oral cavity squamous cell**
4 **carcinoma (OSCC)**

5 Kiana Mahboubi³, Steven C. Nakoneshny², Khara Sauro^{1,2,3,4,5,6}, Samuel Roberts^{3,7}, Rob
6 Hart^{2,3,5}, T Wayne Matthews^{2,3,6}, Joseph Dort^{1,2,3,5,6}, Shamir P Chandarana^{2,3,5,6}

7

8 ¹Department of Community Health Sciences, Cumming School of Medicine, University of
9 Calgary, Calgary, Alberta, Canada

10 ²Ohlson Research Initiative, Arnie Charbonneau Cancer Institute, Cumming School of
11 Medicine, University of Calgary, Calgary, Alberta, Canada

12 ³Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, Cumming
13 School of Medicine, University of Calgary, Alberta, Canada

14 ⁴O'Brien Institute of Public Health, Cumming School of Medicine, University of Calgary,
15 Calgary, Alberta, Canada

16 ⁵Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary,
17 Alberta, Canada

18 ⁶Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of
19 Calgary, Calgary, Alberta, Canada

20 ⁷School of Medicine and Public Health, University of Newcastle, Newcastle, Australia

21

22

23

24 **Key Words:**

25 South Asian; ethnicity; betel nut; oral squamous cell carcinoma (OSCC); oral cancer;

26 head and neck cancer

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47 **Abstract**

48 **Objective:** To compare oncologic outcomes of South Asian (SA) patients treated at a
49 regional cancer centre in Canada, for oral squamous cell carcinoma (OSCC), to the
50 general population.

51 **Methods:** Adult patients who underwent primary surgical resection of OSCC +/-
52 adjuvant treatment between 2009 and 2022 (N=697) were included. SA patients were
53 identified using a validated method and compared to non-SA patients. Baseline
54 characteristics, including betel nut consumption, were compared, and disease-specific
55 survival (DSS) and recurrence-free survival (RFS) were evaluated using Kaplan-Meier
56 methods, with median follow-up time of 36.4 months [SD 31.02]. Cox proportional
57 hazard regression models adjusted for potential confounders. A p-value < 0.05 was
58 considered statistically significant.

59 **Results:** SA patients (9% of cohort, n = 64) were significantly younger and had lower
60 rates of smoking and alcohol consumption compared to non-SA patients. There were no
61 differences in tumor characteristics or the use of adjuvant radiation. SA patients had a
62 two-fold higher risk of recurrence and significantly worse disease-specific survival, even
63 after adjusting for stage and high-risk features [RFS: HR 2.01(1.28 - 3.14), DSS: HR
64 1.79(1.12 - 2.88)]. The consumption of betel nut was not associated with outcomes.

65 **Conclusion:** To our knowledge, this study is the first to compare the oncological
66 outcomes of SA patients with OSCC to non-SA patients. SA patients had significantly
67 worse outcomes, even after controlling for known predictors of recurrence and disease-
68 specific survival. These findings can inform personalized treatment decisions and

69 influence public health policies when managing patients with different ethnic
70 backgrounds.

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92 **Introduction**

93 Head and neck cancer is the sixth most common cancer worldwide and is the
94 most common neoplasm in South Asia (1). Oral cavity cancers account for 30% of all
95 head and neck cancers and 90% of these are oral squamous cell carcinomas (OSCCs)
96 (2,3). These cancers include tumours of the floor of the mouth, anterior tongue, alveolar
97 ridge, retromolar trigone, the hard palate, and the buccal mucosa. According to the
98 World Health Organization, of the 267,000 newly diagnosed OSCCs worldwide, close to
99 40% occurred in South Asia (India, Pakistan, Bangladesh, and Sri Lanka). Furthermore,
100 oral cancer incidence and mortality rates in South Asia are almost twice those of global
101 rates (4).

102 There are a variety of factors that are known to contribute to the development of
103 OSCCs including the consumption of tobacco and alcohol, dental trauma, and human
104 papilloma virus (5). The predominance of OSCCs in South Asia is often attributed to the
105 use of betel nut (6), which can be consumed in a variety of ways but is most often dried
106 and ground into a powder and wrapped in a package known as betel quid or pan,
107 comprised of a mixture of slaked lime, flavouring, and tobacco. Its use is influenced by
108 social acceptability, religious beliefs, and stimulant properties. Betel quid is often stored
109 inside the cheek for hours similar to chewing tobacco. The slaked lime, most often used
110 in India, is particularly problematic as it causes oxidative DNA damage and local
111 mucosal abrasion creating deeper exposure to the carcinogenic components (7).

112 Although there have been improvements in the quality of life of patients with
113 OSCC, both the disease itself as well as its treatment remain morbid with a 5-year

114 overall survival rate of 50 to 60% (8). Current treatments include surgical resection,
115 radiotherapy, chemotherapy, or a combination of these modalities. The primary
116 treatment for early-stage (stage I and II) and advanced-stage (stage III and IV) OSCC is
117 surgical resection of the tumor (9). Previous North American studies have looked at the
118 differences in head and neck cancer disease outcomes according to ethnicity, showing
119 large disparity in mortality rates among African American versus white patients in the
120 United States (10-12). These differences have been attributed to a combination of
121 tumour stage at time of presentation, access to healthcare, and exposure to
122 carcinogens. Nichols *et al.*, reported that even after controlling for tumour stage at time
123 of presentation, African American patients had poorer outcomes, suggesting other
124 intrinsic and extrinsic factors such as genetics and socioeconomic status influence
125 survival in OSCC (13). Arbes *et al.*, accounted for socioeconomic status, which resulted
126 in elimination of the survival disadvantage observed among black patients (14). To
127 date, however, there has been little research that compares oncological outcomes of
128 patients of South Asian (SA) ethnicity with OSCCs compared to other ethnicities.

129 Our regional cancer centre, based in Calgary, Alberta, Canada, treats a high
130 volume of OSCC, in patients with diverse ethnic backgrounds. SA patients represent a
131 significant proportion of patients treated. Given the increased incidence and mortality
132 rates of patients with OSCC in India, the objective of this study was to characterize
133 oncological outcomes among patients of SA ethnicity within our centre and compare
134 these outcomes to patients with OSCC who are not of SA ethnicity.

135

136

137 **Methods and Material**

138 *Patient Selection*

139 Adult patients (age 18 or older) that underwent curative intent primary surgical
140 resection of OSCC at a regional cancer centre were included in the cohort. The set up
141 of this study is that of a regional cancer centre where all head and neck cancers are
142 managed by a multidisciplinary team with expert training and extensive experience.
143 Patient data (n=697) was prospectively collected, and included all patients treated
144 between 2009 to 2022. Patients with recurrent OSCC, a second primary malignancy, a
145 synchronous primary malignancy, or who did not receive surgery as a primary treatment
146 modality were excluded (Fig 1). Variables collected included: patient demographics, risk
147 factors (ethnicity, age, gender, smoking and alcohol status, betel nut use), pathologic
148 data (AJCC 8th edition TNM staging (15) including presence of extranodal extension
149 [ENE], lymphovascular invasion [LVI], perineural invasion [PNI]), and treatment
150 (adjuvant radiation and/or chemotherapy).

151 Patients of SA descent were identified using a multistep approach. First, a
152 previously constructed and validated SA surname list (16) was used to assign SA
153 ethnicity to the patient population. The validated SA surname list was then linked with
154 the patient database to generate a SA patient list. In addition, to ensure the accuracy of
155 the cohort of SA patients, the final study cohort was manually entered into a surname's
156 origin website (17). This list was reviewed by two researchers with SA/middle eastern
157 backgrounds to generate a final list of SA patients. This method has been used
158 successfully to identify ethnic groups in other studies (18, 19).

159 *Statistical Analysis*

160 We interrogated a prospectively collected database of all patients treated for
161 OSCC at the Calgary regional cancer centre. Patient factors, tumor factors, treatment
162 factors and outcomes were analyzed and compared between the SA and non-SA
163 groups.

164 Categorical outcomes were compared between groups using chi-square and
165 continuous outcomes were compared using Student's t-test. Primary outcomes were
166 recurrence-free survival (RFS) and disease specific survival (DSS). RFS was defined as
167 time from surgery to time of last follow-up or local/regional/distant recurrence, whichever
168 came first. DSS was defined as time from surgery to time of last follow-up or death
169 related to OSCC. Difference in RFS and DSS between patients of SA ethnicity and
170 those of non-SA ethnicity were determined by comparing the time-to-event (Kaplan-
171 Meier survival curves) using a log-rank test statistic. These were censored at 3 years of
172 follow-up. Time-to-event outcomes were then adjusted for variables that potentially
173 modified or confounded the relationship between the outcome and exposure (social
174 habits, stage, high risk features on surgical pathology, type of adjuvant treatment) using
175 Cox proportional hazards (PH) regression models. These variables were, in part, based
176 on clinical relevance, having been shown in the literature to potentially modify the
177 oncologic outcomes (20-24). Variables that had a p-value of <0.20 in the univariate
178 model were included in the multivariable model. Stepwise selection methods were used
179 to develop the final models. A p-value < 0.05 was considered statistically significant.
180 Owing to the prospective and rigorous nature of the data collection, missing data was
181 infrequently seen; when missing data was encountered, it was excluded from analysis.
182 Betel nut consumption was not prospectively collected, but due to the published

183 association between consumption and carcinogenesis, a chart review was performed,
184 and where possible, betel nut consumption was collected. A sub-analysis of only
185 patients of SA ethnicity was performed to look for association between betel nut
186 consumption and oncologic outcome (DSS and RFS), by comparing the time-to-event
187 (Kaplan-Meier survival curves) of those that did and did not consume betel nut, using a
188 log-rank test statistic.

189 Statistical Analysis was performed using Stata, version 14 (25). The study was
190 approved by the University of Calgary Conjoint Health Research Ethics Board.

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205 **Results**

206 Using the previously described approach for selecting SA patients, we identified
207 64 SA patients and 632 non-SA patients, which served as the comparison group. We
208 were unable to classify 1 patient as either SA or non-SA (Figure 1). Of the 697 patients
209 that were included, 9% (n=64) were of SA ethnicity. Table 1 describes the cohort by
210 patient and tumour characteristics stratified by ethnicity. The median follow-up time was
211 36.4 months (SD=31.02). SA patients were significantly younger and were less likely to
212 smoke or drink. There were no differences in tumor pathologic characteristics (T-stage,
213 N-stage, ENE, LVI, PNI), nor in the use of adjuvant radiation between the SA and non-
214 SA patients.

215 *Recurrence free survival*

216 Univariate Kaplan-Meier analysis revealed that patients of SA ethnicity had
217 worse RFS [HR=2.35 (1.51–3.65)] than those of non-SA ethnicity (Figure 2A). RFS for
218 SA patients at 3-year follow up was 52%, compared to 76% in the non-SA group
219 (p<0.01). Pathologic characteristics were significantly associated with worsened RFS,
220 regardless of ethnicity: advanced T- stage [HR=2.17 (1.55–3.04)], node positivity [HR=
221 2.98 (1.99–4.45)], presence of ENE [HR=5.39 (3.57– 8.14)], advanced clinical stage
222 [HR = 5.14 (2.82–9.36)], presence of LVI [HR = 2.93 (2.00–4.29)], and presence of PNI
223 [HR = 1.78 (1.24–2.55)] (Figure 2A).

224 After adjusting for the above-mentioned covariates on multivariable analysis, SA
225 ethnicity [HR=2.01 (1.28 - 3.14)], advanced T-stage [HR =1.46 (1.02 - 2.10)], nodal
226 positivity [HR=2.65 (1.77 - 3.99)], and presence of ENE [HR=4.32 (2.75 - 6.78)] were all
227 associated with worsened RFS (Table 2).

228 *Disease-specific survival*

229 On univariate Kaplan-Meier analysis, SA ethnicity was associated with worsened
230 disease-specific survival [HR=2.14 (1.34–3.42)]. DSS for SA patients at 3-year follow up
231 was 59%, compared to 77% in the non-SA group ($p<0.01$). Other negative prognostic
232 features included: advanced T- stage [HR=2.37 (1.66–3.36)], nodal positivity [HR=3.70
233 (2.38–5.74)], presence of ENE [HR=8.04 (5.24– 12.35)], advanced clinical stage [HR =
234 7.67 (3.73–15.78)], presence of LVI [HR = 3.11 (2.11–4.57)], and presence of PNI [HR
235 = 2.20 (1.53–3.18)] (Figure 2B).

236 After adjusting for the above-mentioned covariates on multivariable analysis, SA
237 ethnicity [HR=1.79 (1.12–2.88)], advanced T-stage [HR = 1.64 (1.10–2.43)], node
238 positivity [HR=3.97 (2.44–6.45)], and presence of ENE [HR=16.40 (9.00–29.91)]
239 predicted worsened DSS (Table 3).

240 *Pattern of failure in those that recurred*

241 Among the 193 patients that developed a recurrence, 86% of patients of SA
242 ethnicity recurred either locally or regionally, compared to the 87% in the patients of
243 non-SA ethnicity. Conversely, 14% of patients of SA ethnicity and 13% of patients of
244 non-SA ethnicity had distant recurrence. The difference in pattern of failure was not
245 significant.

246 *Betel nut use in SA patients*

247 Chart review of the 64 SA patients revealed that 23 used betel nut, 28 did not
248 use betel nut, and 13 did not have betel nut use reported. Univariate analysis of just the
249 SA patients did not predict a difference in RFS or DSS between those who used betel
250 nut and those who did not (Figure 3).

251 **Discussion**

252 This study demonstrated that patients of SA ethnicity had significantly worse
253 survival outcomes and were twice as likely to recur compared to non-SA patients even
254 after accounting for other known factors contributing to poor oncological outcomes. The
255 SA community is one of the largest and fastest growing minority groups in Canada
256 based on the 2021 census (26). Considering the migration patterns within the South
257 Asian community and their correlation with the prevalence of OSCC, it's important to
258 acknowledge the potential impact on health trends in Canada. Understanding these
259 patterns, can help promote public health initiatives and ensure that the unique needs of
260 the South Asian population are met, fostering a more inclusive and supportive
261 environment. Studies conducted in Malaysia (27,28), UK (29), Australia (30), and South
262 Africa (31) indicate that individuals of SA heritage are at higher risk of oral cancer than
263 the non-SA population in those countries. A study in British Columbia, which has one of
264 the highest South Asian immigrant populations in Canada, demonstrated a relative risk
265 of developing OSCC of 1.33 and 1.66 for South Asian men and women, respectively, as
266 compared with the non-SA population (32). Anecdotally, the senior authors at our
267 centre, who treat high volumes of OSCC, felt that year over year, SA patients
268 represented a disproportionately larger ethnicity group than other ethnicities, and were
269 recurring more frequently. The decision to formally evaluate outcomes based on SA
270 ethnicity was therefore born out of concern for a potentially at-risk population, in hopes
271 to validate the need for a more tailored approach to treating this group of patients, as
272 well as to build awareness and inform public health policy.

273 This study uniquely evaluates differences in oncological outcomes of patients of
274 SA ethnicity affected by OSCCs compared to patients of non-SA ethnicity. This results

275 suggest that, in Canada, SA ethnicity is an independent predictor of recurrence-free and
276 worse disease-specific survival, when compared to non-SA patients. The study is
277 conducted within the framework of a regional cancer center, where a dedicated
278 multidisciplinary team, possessing expert training and extensive experience, oversees
279 the management of all head and neck cancers. This setup intentionally minimizes bias
280 for selection for more complicated cases. Stage of diagnosis is regarded as one of the
281 most important predictors of oral cancer survival with a significantly improved 5-year
282 survival rate for early-stage disease (71.4%) than for late-stage disease (21.8%) (33). In
283 this study, when comparing baseline characteristics of SA and non-SA patients,
284 oncological parameters such as T-Stage, N-stage, ENE, LVI and PNI were similar which
285 suggests they were not the primary drivers of differences in recurrence and worse
286 survival in SA patients. This association was also found in multivariable analysis. The
287 similarity in these variables between groups also infers that there are no discrepancies
288 in access to care, which would likely lead to a delayed presentation, with more
289 advanced disease at time of presentation. Although, the initial presenting burden of
290 disease is an imperfect tool to estimate access to care, in a universal health care
291 system, issues such as treatment delay, is relatively uniform across all sub-populations.
292 Interestingly, features that are typically protective against developing OSCC such as
293 younger age and non-smoking status were more common in SA patients. Despite this,
294 being SA resulted in a two-fold increase in recurrence and decrease in OSCC survival.
295 As expected, patients with advanced T stage (T3/4), nodal disease and ENE had both
296 worsened DSS and RFS, validating that the patient cohort in this study is representative
297 of the greater head and neck cancer population. Disease stage at time of diagnosis has

298 been previously identified as a causative factor in poorer oncological outcome in
299 minority groups (34). In this study, even after controlling for disease stage, SA ethnicity
300 remained as an independent factor in predicting survival and recurrence.

301 Several factors potentially contribute to the poorer outcomes of OSCC in SA
302 patients. One of the major factors is thought to be the use of betel nut in the SA culture,
303 which is commonly consumed in the form of betel quid. Although the added tobacco
304 plays a significant role in the development of OSCCs, studies have suggested that betel
305 products, which contain arecoline and 3-(methylnitrosamino) propionitrile, may have an
306 independent carcinogenic effect (35) resulting in malignant transformation of oral
307 submucosal fibrosis (OSMF). The potential for malignant transformation resulting in
308 OSCC has been reported to be as high as 7 to 13% (36). Although the exact
309 mechanism is not well understood, betel nut is thought to induce *c-jun* proto-oncogene
310 expression in human mucosal fibroblasts (37). The fibrosis itself can result in decreased
311 vascularity and hypoxia thus mediating mutated cell divisions (38). This study did not
312 find any differences on either recurrence or survival among patients of SA ethnicity
313 based on betel nut use; however, given that betel nut consumption was not consistently
314 reported in patient charts, further investigation with larger numbers and more consistent
315 reporting is required to verify this finding.

316 Pattern of recurrence describes whether a patient recurs locally, regionally, or at
317 a distant site. Given that betel nut is often stored inside the cheek for prolonged periods
318 of time, one would expect SA patients to recur locoregionally if betel nut use is the
319 causative factor. In our study population, the majority of recurrences in the SA
320 population were local/regional however, the proportion of patients that recurred

321 locoregionally was not significantly different between SA and non-SA patients. This
322 suggests that regardless of the causative agent for OSCC, recurrences are more likely
323 to manifest as local/regional rather than distant disease.

324 A strength of this study relies on the rigorous, prospective collection of data
325 including patient related factors, tumor factors, treatment factors and oncologic
326 outcomes. A limitation is the relatively small sample size within the SA cohort. A larger
327 multicentre study could yield more definitive results on this issue. Given the absence of
328 race or ethnicity information in many databases used in health research, surnames are
329 frequently employed as a proxy when investigating healthcare patterns within ethnic
330 populations. Despite this, a limitation arises in potentially excluding individuals of South
331 Asian background who may have undergone name changes. However, it should be
332 noted that in Canada, according to the 2021 census, 76% of South Asians were recent
333 immigrants born outside of Canada (26), and therefore, the likelihood of experiencing a
334 name change is low. This study also did not differentiate between SA immigrants and
335 Canadian born people of SA ethnicity (first and subsequent generations) which hinders
336 the ability to distinguish between the role of environment versus inheritance on the
337 findings. There are important factors related to immigration status that may mediate the
338 findings of this study, some of which include betel nut use, environmental factors and
339 genetic factors. Although, there is no specific data on the use of betel nut in Canada,
340 UK and Australian data shows that it is commonly used among first generation
341 immigrants and its use is reduced in subsequent generations (39). However, in younger
342 generations, the form of consumption is tilting towards ingestion which may result in
343 higher rates of esophageal cancers (39). As such, a more granular study on time since

344 immigration and mode of betel nut use would be informative. In addition to
345 environmental factors, genetics can also play a role in the poor outcomes observed in
346 South Asian patients with OSCC. However, no specific genes have been identified as
347 predisposing factors for OSCC in the SA population and the hereditary factors that
348 contribute to the disease are largely unknown. While most cases of OSCC occur
349 sporadically, certain families with a high preponderance of the disease have been found
350 to carry oncogenes such as *VAV2* and *IQGAP1* with an autosomal dominance
351 penetrance (40). Moreover, with the emergence of precision medicine, there has been a
352 growing interest in identifying diagnostic and prognostic biomarkers for OSCC. One
353 such biomarker is microRNA (miRNA), a large group of small single-stranded non-
354 coding endogenous RNAs that play a role in post-transcriptional gene regulation.
355 Upregulation of miRNAs is thought to contribute to OSCC resistance to chemoradiation
356 and recurrence (41). Our centre is involved in banking the tumors of all consecutive
357 OSCC patients and intends to explore the potential molecular basis of poor OSCC
358 outcomes in the SA population.

359 The findings of this study reveal that patients with SA ethnicity experience
360 significantly poorer outcomes compared to the non-SA cohort, even after accounting for
361 other predictors of poor outcome. To gain a more comprehensive understanding of the
362 intricate interplay between ethnicity, environmental exposure, and genetic predisposition
363 in OSCC outcomes, further research is imperative. Such research could pave the way
364 for personalized treatment decisions and patient counseling, as well as the formulation
365 of public health policies that serve to assist vulnerable and at-risk populations.

366

367 **Conclusion**

368 Patients of SA ethnicity had worse outcomes (higher risk of recurrence and
369 worsened survival) than patients with non-SA ethnicity, even after controlling for other
370 known predictors of poor outcome in OSCC. These finding can inform more
371 individualized treatment decision making and impact public health policy when serving
372 heterogeneous patient populations.

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390 **References**

- 391 1. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. *CA: A*
392 *Cancer Journal for Clinicians*. 2005;55(2):74-108.
- 393 2. Moore S, Johnson N, Pierce A, Wilson D. The epidemiology of tongue cancer: a
394 review of global incidence. *Oral Diseases*. 2008;6(2):75-84.
- 395 3. Rapidis A. Head and Neck Cancer: Multimodality Management. In: Bernier J,
396 editor. Multidisciplinary management of oral cavity and maxillary sinus cancers.
397 New York, NY: Springer Science 1 Business Media, LLC; 2011.
- 398 4. Gupta B, Ariyawardana A, Johnson NW. Oral cancer in India continues in
399 epidemic proportions: evidence base and policy initiatives. *Int Dent J*. 2013
400 Jan;63(1):12-25.
- 401 5. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. *Oral*
402 *Oncology*. 2009;45(4-5):309-316.
- 403 6. IARC monographs on the evaluation of the carcinogenic risk of chemicals to
404 humans. Vol. 37. Tobacco habits other than smoking; Betel-quid and Betel-nut
405 chewing; and some related nitrosamines. *Food and Chemical Toxicology*.
406 1986;24(8):885-886.
- 407 7. Chen PH, Mahmood Q, Mariottini GL. Betel quid and oral cancer: a review with
408 emphasis on its prevalence, etiology, and carcinogenesis. *J Environ Sci Health C*
409 *Environ Carcinog Ecotoxicol Rev*. 2016;34(4):249-261.
- 410 8. Epstein JB, Thariat J, Bensadoun RJ, et al. Oral squamous cell carcinoma: early
411 detection and intervention. *Can J Otolaryngol Head Neck Surg*. 2011;39(4):275-
412 281.

- 413 9. National Comprehensive Cancer Network. Head and neck cancers (version
414 3.2021). Accessed May 4, 2023.
415 https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
- 416 10. Yu AJ, Choi JS, Swanson MS, et al. Association of Race/Ethnicity, Stage, and
417 Survival in Oral Cavity Squamous Cell Carcinoma: A SEER Study. *OTO Open*.
418 2019;3(4).
- 419 11. Goodwin WJ, Thomas GR, Parker DF, et al. Unequal burden of head and neck
420 cancer in the United States. *Head Neck*. 2008;30:358-371.
- 421 12. Molina MA, Cheung MC, Perez EA, et al. African American and poor patients
422 have a dramatically worse prognosis for head and neck cancer: an examination
423 of 20,915 patients. *Cancer*. 2008;113:2797-2806.
- 424 13. Nichols AC, Bhattacharyya N. Racial differences in stage and survival in head
425 and neck squamous cell carcinoma. *Laryngoscope*. 2007;117:770-775.
- 426 14. Arbes SJ Jr, Olshan AF, Caplan DJ, et al. Factors contributing to the poorer
427 survival of black Americans diagnosed with oral cancer (United States). *Cancer*
428 *Causes Control* 1999;10:513–523.
- 429 15. AJCC. AJCC Cancer Staging Manual. 8th ed. Springer; 2017.
- 430 16. Shah BR, Chiu M, Amin S, Ramani M, Sadry S, Tu JV. Surname lists to identify
431 South Asian and Chinese ethnicity from secondary data in Ontario, Canada: a
432 validation study. *BMC Medical Research Methodology*. 2010;10(1).
- 433 17. Surnames Meanings, Origins & Distribution Maps. Forebears.io. Published 2012.
434 <https://forebears.io/surnames>
- 435 18. Auluck A, Hislop G, Bajdik C, Hay J, Bottorff JL, Zhang L, Rosin MP. Gender-

- 436 and ethnicity-specific survival trends of oral cavity and oropharyngeal cancers in
437 British Columbia. *Cancer Causes Control*. 2012;23(12):1899-1909.
- 438 19. Hislop GT, Bajdik CD, Regier MD, Barroetavena MC. Ethnic differences in
439 survival for female cancers of the breast, cervix and colorectum in British
440 Columbia, Canada. *Asian Pac J Cancer Prev*. 2007;8(2):209-214.
- 441 20. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced
442 head and neck cancers: a comparative analysis of concurrent postoperative
443 radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#
444 9501). *Head Neck*. 2005;27(10):843-850.
- 445 21. Cooper JS, Pajak TF, Forastiere A, et al. Precisely defining high-risk operable
446 head and neck tumors based on RTOG #85-03 and #88-24: targets for
447 postoperative radiochemotherapy?. *Head Neck*. 1998;20(7):588-594.
- 448 22. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and
449 time factors of surgery plus radiotherapy in advanced head-and-neck cancer. *Int*
450 *J Radiat Oncol Biol Phys*. 2001;51(3):571-578.
- 451 23. Rosenthal DI, Liu L, Lee JH, et al. Importance of the treatment package time in
452 surgery and postoperative radiation therapy for squamous carcinoma of the head
453 and neck. *Head Neck*. 2002;24(2):115-126.
- 454 24. Langendijk JA, de Jong MA, Leemans CR, et al. Postoperative radiotherapy in
455 squamous cell carcinoma of the oral cavity: the importance of the overall
456 treatment time. *Int J Radiat Oncol Biol Phys*. 2003;57(3):693-700.
- 457 25. StataCorp. 2023. Stata Statistical Software: Release 18. College Station, TX:
458 StataCorp LLC.

- 459 26. Government of Canada, Statistics Canada. Census Profile, 2021 Census -
460 Canada [Country] and Canada [Country]. Statcan.gc.ca. Published 2021.
461 Accessed February 8, 2023. [https://www12.statcan.gc.ca/census-
recensement/2016/dp-
pd/prof/details/page.cfm?Lang=E&Geo1=PR&Code1=01&Geo2=PR&Code2=01
&Data=Count&SearchText=Canada&SearchType=Begins&SearchPR=01&B1=Et
hnic%20origin&TABID=1](https://www12.statcan.gc.ca/census-
462 recensement/2016/dp-
463 pd/prof/details/page.cfm?Lang=E&Geo1=PR&Code1=01&Geo2=PR&Code2=01
464 &Data=Count&SearchText=Canada&SearchType=Begins&SearchPR=01&B1=Et
465 hnic%20origin&TABID=1)
- 466 27. Zain RB, Ikeda N, Razak IA, et al. A national epidemiological survey of oral
467 mucosal lesions in Malaysia. *Community Dentistry and Oral Epidemiology*.
468 1997;25(5):377-383.
- 469 28. Ali TBT, Jalaliuddin RLR, Razak IA, Zain RB. Prevalence of Oral Precancerous
470 and Cancerous Lesions in Elderly Malaysians. *Asia Pacific Journal of Public
471 Health*. 1997;9(1):24-27.
- 472 29. Warnakulasuriya S. Betel nut use following migration and its consequences.
473 *Addiction Biology*. 2002;7(1):127-132.
- 474 30. Petti S. Lifestyle risk factors for oral cancer. *Oral Oncology*. 2009;45(4-5):340-
475 350.
- 476 31. Van Wyk CW, Stander I, Padayachee A, Grobler-Rabie AF. The betel nut
477 chewing habit and oral squamous cell carcinoma in South African Indians. A
478 retrospective study. *South African Medical Journal* 1993;83(6):425-429.
- 479 32. Rock LM, Datta M, Laronde DM, Carraro A, Korbelik J, Harrison A, Guillaud M.
480 Conducting community oral cancer screening among South Asians in British
481 Columbia. *J Cancer Educ*. 2012;27(2):354-358.

- 482 33. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and
483 prognosis for head and neck cancer in the United States: A site-specific analysis
484 of the SEER database. *International Journal of Cancer*. 2004;114(5):806-816.
- 485 34. Shiboski CH, Schmidt BL, Jordan RCK. Racial disparity in stage at diagnosis and
486 survival among adults with oral cancer in the US. *Community Dentistry and Oral
487 Epidemiology*. 2007;35(3):233-240.
- 488 35. Senevirathna K, Pradeep R, Jayasinghe YA, et al. Carcinogenic Effects of Betel
489 Nut and Its Metabolites: A Review of the Experimental Evidence. *Clinics and
490 Practice*. 2023;13(2):326-346.
- 491 36. Phulari RGS, Dave EJ. A systematic review on the mechanisms of malignant
492 transformation of oral submucous fibrosis. *Eur J Cancer Prev*. 2020;29(5):470-
493 473.
- 494 37. Warnakulasuriya S. Betel nut use: an independent risk factor for oral
495 cancer. *BMJ*. 2002;324(7341):799-800.
- 496 38. Veeravarmal V, Austin R, Siddavaram N, Thiruneelakandan S, Nassar MHM.
497 Caspase-3 expression in normal oral epithelium, oral submucous fibrosis and
498 oral squamous cell carcinoma. *Journal of Oral and Maxillofacial Pathology*.
499 2016;20(3):445.
- 500 39. Auluck A, Hislop G, Poh C, Zhang L, Rosin MP. Betel nut and betel quid chewing
501 among South Asian immigrants to Western countries and its implications for oral
502 cancer screening. *Rural Remote Health*. 2009;9(2):1118.
- 503 40. Huang Y, Zhao J, Mao G, et al. Identification of novel genetic variants
504 predisposing to familial oral squamous cell carcinomas. *Cell Discovery*.

505 2019;5(1).

506 41. Dioguardi M, Spirito F, Sovereto D, et al. The Prognostic Role of miR-31 in Head
507 and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis with
508 Trial Sequential Analysis. *Int J Environ Res Public Health*. 2022;19(9):5334.

509

Tables

Table 1. Patient Demographics

Characteristic		Total n=696	Non-South Asian n=632	South Asian n=64	p-value
Gender					ns
	Female	265	244	21	
	Male	431	388	43	
Age					0.0194
	Mean [SD]	62.4 [13.34]	62.8 [13.24]	58.0 [13.72]	
	Range	23.6 - 96.3	23.6 - 96.3	25.8 - 79.3	
Smoking History					<0.0001^
	Never Smoked	191	153	38	
	Ex-smoker	258	244	14	
	Current Smoker	227	216	10	
	Not Stated	21	19	2	
Betel Nut Usage					N/A
	Yes	23	N/A	23	
	No	28	N/A	28	
	Not Stated	13	N/A	13	
Drinking History					<0.0001^
	Never Drinker	155	121	34	
	Ex-drinker	70	66	4	
	Current Drinker	411	395	16	
	Not Stated	60	50	10	
Pathologic T stage					ns
	T0/Tis	31	29	2	
	T1	234	217	17	
	T2	169	149	20	
	T3	83	76	7	
	T4	171	153	18	
	Tx	8	8	0	

Pathologic N stage					ns
	N0	268	245	23	
	N1	70	64	6	
	N2	138	121	17	
	N3	29	25	4	
	Nx	186	177	14	
Pathologic Clinical Stage					ns
	Stage 0	4	3	1	
	Stage I	74	70	4	
	Stage II	87	77	10	
	Stage III	80	73	7	
	Stage IV	260	232	28	
	Not Stated	191	177	14	
Extracapsular Spread					ns
	ECS not present	146	131	15	
	ECS present	93	81	12	
	N/A (eg N0 neck)	457	420	37	
Lymphovascular Invasion					ns
	Absent	500	456	44	
	Present	112	102	10	
	Not Stated	84	74	10	
Perineural Invasion					ns
	Absent	403	363	40	
	Present	202	185	17	
	Not Stated	91	84	7	
Treatment					ns
	Surgery Alone	427	389	38	
	Surgery + Radiation	180	166	14	
	Surgery + Chemoradiation	89	77	12	

^ Wilcoxon rank-sum test; * Fisher's exact test; ns= not significant

Table 2: Cox Regression Analysis for Recurrence Free Survival

Variable	Univariate Analysis		Multivariable Analysis	
	Hazard ratio [95% CI]	p-value	Hazard ratio [95% CI]	p-value
Ethnicity, non-SA vs SA	2.35 [1.51 - 3.65]	<0.0001	2.01 [1.28 - 3.14]	0.002
Pathologic T Classification, pT0- pT2 vs pT3-pT4	2.17 [1.55 - 3.04]	<0.0001	1.46 [1.02 - 2.10]	0.04
Pathologic Node Positivity, pN0 vs pN+	4.81 [3.08 - 7.51]	<0.0001	–	–
Clinical Stage, I/II vs III/IV	5.14 [2.82 - 9.36]	<0.0001	–	–
Lymphovascular Invasion, no vs yes	2.93 [2.00 - 4.29]	<0.0001	–	–
Perineural Invasion, no vs yes	1.78 [1.24 - 2.55]	0.002	–	–
Extracapsular Spread (ref: N0)				
N+, ECS–	2.98 [1.99 - 4.45]	<0.0001	2.65 [1.77 - 3.99]	<0.0001
N+, ECS+	5.39 [3.57 - 8.14]	<0.0001	4.32 [2.75 - 6.78]	<0.0001
Treatment Modality (ref: Surgery Alone)				
Surgery + Radiation	2.30 [1.57 - 3.36]	<0.0001	–	–
Surgery + Chemoradiation	2.84 [1.83 - 4.34]	<0.0001	–	–

Table 3: Cox Regression Analysis for Disease Specific Survival

Variable	Univariate Analysis		Multivariable Analysis	
	Hazard ratio [95% CI]	p-value	Hazard ratio [95% CI]	p-value
Ethnicity, non-SA vs SA	2.14 [1.34 - 3.42]	0.001	1.79 [1.12 - 2.88]	0.016
Pathologic T Classification, pT0- pT2 vs pT3-pT4	2.37 [1.66 - 3.36]	<0.0001	1.64 [1.10 - 2.43]	0.015
Pathologic Node Positivity, pN0 vs pN+	6.10 [3.75 - 9.92]	<0.0001	–	–
Clinical Stage, I/II vs III/IV	7.67 [3.73 - 15.78]	<0.0001	–	–
Lymphovascular Invasion, no vs yes	3.11 [2.11 - 4.57]	<0.0001	–	–
Perineural Invasion, no vs yes	2.20 [1.53 - 3.18]	<0.0001	–	–
Bone Invasion, no vs yes	1.80 [1.11 - 2.92]	0.017	–	–
Extracapsular Spread (ref: N0)				
N+, ECS–	3.70 [2.38 - 5.74]	<0.0001	3.97 [2.44 - 6.45]	<0.0001
N+, ECS+	8.04 [5.24 - 12.35]	<0.0001	16.40 [9.00 - 29.91]	<0.0001
Treatment Modality (ref: Surgery Alone)				
Surgery + Radiation	2.28 [1.53 - 3.41]	<0.0001	0.85 [0.53 - 1.36]	ns
Surgery + Chemoradiation	3.14 [2.00 - 4.94]	<0.0001	0.27 [0.14 - 0.53]	<0.0001

ns= not significant